The Ellipta inhaler
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
- Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD
- Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD
Tweets from GSK
-
GSK @GSK
#DYK if 90% of people in a population are vaccinated, it makes it difficult for a disease to spread. Fabiana goes #BehindTheScience of ‘herd immunity’ #vaccineswork
about 15 hours ago -
GSK @GSK
14 diseases you almost forgot about #vaccineswork #ThrowbackThursday #tbt cdc.gov/vaccines/paren…
about 19 hours ago
-
GSK @GSK
Let’s get #readytobeatmalaria on #WorldMalariaDay and every day cards.twitter.com/cards/ob0hpq/5…
about 1 day ago
